NDAORALTABLET, EXTENDED RELEASE
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2
Data completeness
5/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INVOKAMET XR is a fixed-dose combination tablet containing canagliflozin (a sodium-glucose cotransporter 2 inhibitor) and metformin hydrochloride (an extended-release biguanide), approved by the FDA on September 20, 2016. The product is indicated for type 2 diabetes mellitus management, combining two complementary mechanisms of action to improve glycemic control. Canagliflozin works by promoting urinary glucose excretion while metformin reduces hepatic glucose production and improves insulin sensitivity. INVOKAMET XR represents a convenient once-daily alternative to dual therapy for patients requiring both agents.
$0.0BPart D
3.3 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
Started Nov 2020
276 enrolled
Diabetes Mellitus
A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function
Started Mar 2008
40 enrolled
Renal InsufficiencyHealthy
Why This Matters for Your Career
Worked on INVOKAMET XR at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.